Digipath
CHM Cannabis
Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 12/7/2018 10:29:36 AM - Followers: 68 - Board type: Free - Posts Today: 0
Digipath
CHM Cannabis
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Statement of Changes in Beneficial Ownership (4) 12/04/2018 05:52:11 PM
ENTA News: Annual Report (10-k) 11/29/2018 04:10:16 PM
ENTA News: Current Report Filing (8-k) 11/26/2018 04:08:43 PM
ENTA News: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 11/26/2018 04:01:00 PM
ENTA News: Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve H... 11/13/2018 11:40:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1717  Sticky Note ENTA FY4Q18 results—GAAP EPS=$1.30: DewDiligence 11/26/18 04:08:15 PM
#1724   That's the highest-ever weekly figure, according to IMS. DewDiligence 12/07/18 10:29:36 AM
#1723   ABBV's Mavyret weekly NRx market share of the guyschmid 12/07/18 09:17:56 AM
#1722   ENTA’s General Counsel exercised and held $150K of DewDiligence 12/06/18 08:52:27 PM
#1721   ENTA SVP exercised and held $150K of stock yesterday: DewDiligence 12/04/18 07:56:35 PM
#1720   ABBV's Mavyret weekly NRx market share of the guyschmid 11/30/18 08:41:39 AM
#1719   ENTA’s enterprise value at current share price ~$1.44B: #msg-145176914. DewDiligence 11/29/18 05:09:56 PM
#1718   ENTA FY4Q18 CC transcript: DewDiligence 11/27/18 09:17:16 AM
#1717   ENTA FY4Q18 results—GAAP EPS=$1.30: DewDiligence 11/26/18 04:08:15 PM
#1716   ENTA’s latest corporate slides: DewDiligence 11/25/18 07:17:16 PM
#1715   ABBV's Mavyret weekly NRx market share of the guyschmid 11/16/18 08:39:11 AM
#1714   Mavyret data from AASLD: DewDiligence 11/13/18 12:17:54 PM
#1713   ABBV's Mavyret weekly NRx market share of the guyschmid 11/09/18 08:41:04 AM
#1712   ABBV's Mavyret weekly NRx market share of the guyschmid 11/02/18 08:59:57 AM
#1711   ABBV 3Q18 results—HCV sales=$862M (vs ABBV’s $850M guidance): DewDiligence 11/02/18 08:14:23 AM
#1710   ABBV's Mavyret weekly NRx market share of the guyschmid 10/26/18 09:11:45 AM
#1709   EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:48:30 AM
#1708   ABBV's Mavyret weekly NRx market share of the guyschmid 10/19/18 09:28:07 AM
#1707   From the Japanese drug email list - Rocky3 10/14/18 10:44:33 PM
#1706   Mavyret’s US new-patient share=53.4%—the highest-ever weekly figure—in th DewDiligence 10/12/18 09:09:48 AM
#1705   https://abbvie.referrals.selectminds.com/landingpages/sales-opportunities-at-abbvie-108 scroll do willyw 10/10/18 12:40:46 PM
#1704   ...Abbvie is hiring people for the HCV China DewDiligence 10/10/18 12:32:25 PM
#1703   Seeing the trial set up (and fairly early willyw 10/10/18 12:20:36 PM
#1702   Luly said the phase-2a RSV trial will start DewDiligence 10/10/18 12:03:43 PM
#1701   A Phase 2a Study to Evaluate EDP-938 in willyw 10/10/18 11:52:04 AM
#1700   Mavyret 9/28/18 script update: #msg-144060008. DewDiligence 10/08/18 11:16:08 AM
#1699   The exercise price of a given option is DewDiligence 10/08/18 10:43:56 AM
#1698   Thanks Dew, so the exercise price of $34.70 Bickema 10/08/18 10:37:02 AM
#1697   Exercising options early, at a lower market price, DewDiligence 10/08/18 10:35:22 AM
#1696   Dew, What is the advantage of exercising these Bickema 10/08/18 10:25:28 AM
#1695   $120K* exercise-and-hold transaction by General Counsel: DewDiligence 10/02/18 05:39:40 PM
#1694   GILD will launch Harvoni/Epclusa authorized generics for US DewDiligence 09/24/18 10:01:05 AM
#1693   Any update today? tmoney2555 09/21/18 03:44:15 PM
#1692   ABBV's Mavyret weekly NRx market share of the guyschmid 09/14/18 09:33:44 AM
#1691   ABBV's Mavyret weekly NRx market share of the guyschmid 09/07/18 09:01:57 AM
#1690   ABBV's Mavyret weekly NRx market share of the vinmantoo 09/06/18 12:02:35 PM
#1689   New corporate slide set: DewDiligence 09/06/18 11:11:39 AM
#1688   EDP-938 data to be presented at RSV conference: DewDiligence 09/05/18 09:23:08 AM
#1687   ABBV's Mavyret weekly NRx market share of the guyschmid 09/04/18 09:14:47 AM
#1686   ABBV's Mavyret weekly NRx market share of the guyschmid 08/24/18 07:54:35 AM
#1685   The small amount of calendar-2Q18 Viekira royalty revenue DewDiligence 08/11/18 12:10:51 PM
#1684   Did anyone do the calculations? The 57.3 royalty DaveAu 08/11/18 10:27:44 AM
#1683   ENTA's EV is only $1.68B: #msg-142808471. DewDiligence 08/09/18 05:13:27 PM
#1682   ENTA has disclosed the Mavyret/Glecaprevir royalty-rate tiers: #msg-142808661. DewDiligence 08/09/18 05:12:47 PM
#1681   ENTA CC notes: #msg-142751191. DewDiligence 08/07/18 05:46:05 PM
#1680   ENTA quarterly numbers ought to be viewed positively, DewDiligence 08/07/18 04:26:45 PM
#1679   How is this viewed? I would think JK2016 08/07/18 04:23:30 PM
#1678   ENTA FY3Q18 results—royalty revenue=$57.3M (+30% QoQ); GAAP EPS=$0.97: DewDiligence 08/07/18 04:09:08 PM
#1677   Other PBMs haven't yet released their planned 2019 DewDiligence 08/07/18 03:12:21 PM
#1676   Good analysis. Have other PBMs released their 2019 DaveAu 08/07/18 03:06:56 PM
#1675   More on same subject: DewDiligence 08/07/18 01:57:30 PM
PostSubject